{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-048144","form_type":"8-K","ticker":"MOVE","cik":"0001734750","company_name":"Corvex, Inc.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.855507+00:00","generated_at":"2026-06-23T23:56:33.906166+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Movano Q2 net loss $6.9M; advances Ring beta tests, hypoxia study meets FDA SpO2 accuracy","bullets":["Net loss $6.9M ($0.21/sh) vs $4.7M ($0.15/sh) in Q2 2021; no revenue as development-stage company.","Cash $21.3M at June 30, 2022, down from $33.6M at Dec 31, 2021.","Plans DTC launch of Movano Ring in H1 2023; beta partners include Stanford, major pharma, diabetes device firm.","Hypoxia study with UCSF: Ring achieved 2% SpO2 error margin (FDA requires 4%); larger pivotal study planned.","Two new patents granted for SoC; planning BP and glucose clinical studies in Q3 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-048144","json":"https://secwatch.observer/filing/0001213900-22-048144.json","markdown":"https://secwatch.observer/filing/0001213900-22-048144.md","text":"https://secwatch.observer/filing/0001213900-22-048144.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1734750/000121390022048144/0001213900-22-048144-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1734750/000121390022048144/ea164341-8k_movanoinc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:56:33.906166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}